Avicenna Biosciences
United States
activeunknown
unknown
Stage
2022
Founded
2
Investors
About
Avicenna Biosciences uses a machine-learning-driven medical chemistry platform to screen and optimize candidate drug molecules, accelerating drug discovery and reducing toxicity risks. The company has developed a new Rho kinase (ROCK) inhibitor aimed at neurodegenerative disease and is conducting IND-enabling studies.
Explore Avicenna Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.